Rchr
J-GLOBAL ID：202001018089900371
Update date: Feb. 01, 2024
Ogihara Koichiro
オギハラ コウイチロウ | Ogihara Koichiro
Affiliation and department：
Job title：
共同研究員
Research theme for competitive and other funds (2)：
- 2021 - 2023 Establishing New Therapeutic Strategy for Urothelial Carcinoma
- 2017 - 2019 The establishment of new therapeutic strategy for bladder cancer targeting to cancer stem cell
Papers (48)：
-
Minami Omura, Eiji Kikuchi, Keisuke Shigeta, Koichiro Ogihara, Kyohei Hakozaki, Satoshi Hara, Suguru Shirotake, Hiroki Ide, Shunsuke Yoshimine, Takashi Ohigashi, et al. Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer. Japanese journal of clinical oncology. 2022. 52. 4. 388-396
-
Hiroki Ide, Eiji Kikuchi, Koichiro Ogihara, Naoya Niwa, Keisuke Shigeta, Tsukasa Masuda, Yuto Baba, Ryuichi Mizuno, Mototsugu Oya. Urinary pH is an independent predictor of upper tract recurrence in non-muscle-invasive bladder cancer patients with a smoking history. Scientific Reports. 2021. 11. 1
-
Tetsushi Murakami, Eiji Kikuchi, Hiroki Ide, Yuta Umezawa, Takayuki Takahashi, Mizuki Izawa, Kyohei Hakozaki, Keisuke Shigeta, Koichiro Ogihara, Hiroaki Kobayashi, et al. Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma. BJUI Compass. 2021. 2. 5. 322-330
-
Ryohei Kufukihara, Eiji Kikuchi, Koichiro Ogihara, Keisuke Shigeta, Mototsugu Oya. ASO Author Reflections: Previous History of Non-urothelial Malignancy May Provide Predictive Information of Worse Clinical Outcome for Initially Diagnosed Non-Muscle Invasive Bladder Cancer. Annals of surgical oncology. 2021. 28. 9. 5360-5361
-
Yuto Baba, Eiji Kikuchi, Keisuke Shigeta, Koichiro Ogihara, Masashi Matsushima, Yui Nishimoto, Yasuaki Murata, Hirotaka Asakura, Masafumi Oyama, Ryuichi Mizuno, et al. Effects of transurethral resection under general anesthesia on tumor recurrence in non-muscle invasive bladder cancer. International journal of clinical oncology. 2021. 26. 11. 2094-2103
ｍore...
MISC (23)：
-
久冨木原良平, 菊地栄次, 菊地栄次, 茂田啓介, 荻原広一郎, 有田祐起, 秋田大宇, 鈴木達也, 水野隆一, 大家基嗣, et al. 膀胱癌の筋層浸潤評価におけるVI-RADSと膀胱鏡検査の役割. 泌尿器画像診断・治療技術研究会プログラム・抄録. 2021. 8th
-
Koichiro Ogihara, Eiji Kikuchi, Takashi Okabe, Ryo Yamashita, Shunsuke Yoshimine, Suguru Shirotake, Ryuto Nakazawa, Kazuhiro Matsumoto, Ryuichi Mizuno, Satoshi Hara, et al. PRETREATMENT ABSOLUTE MONOCYTE COUNT IS A NOVEL BIOMARKER FOR PREDICTING WORSE CLINICAL OUTCOME IN CHEMO-RESISTANT UROTHELIAL CARCINOMA PATIENTS TREATED WITH PEMBROLIZUMAB. JOURNAL OF UROLOGY. 2020. 203. E741-E742
-
Koichiro Ogihara, Eiji Kikuchi, Toshikazu Takeda, Kazuhiro Matsumoto, Hideyuki Saya, Mototsugu Oya. SULFASALAZINE COULD MODULATE THE CD44V9-XCT SYSTEM AND ENHANCE CDDP-INDUCED CYTOTOXIC EFFECTS IN METASTATIC BLADDER CANCER; A NOVEL THERAPEUTIC STRATEGY FOR METASTATIC BLADDER CANCER. JOURNAL OF UROLOGY. 2020. 203. E2-E2
-
Tadatsugu Anno, Eiji Kikuchi, Koichiro Ogihara, Mototsugu Oya. SITE SPECIFIC DIFFERENCES IN SURVIVAL AMONG BLADDER, RENAL PELVIC, AND URETERAL UROTHELIAL CARCINOMA PATIENTS TREATED WITH RADICAL SURGERY. JOURNAL OF UROLOGY. 2019. 201. 4. E720-E720
-
Shigeta Keisuke, Eiji Kikuchi, Masayuki Hagiwara, Takayuki Abe, Koichiro Ogihara, Ryuichi Mizuno, Mototsugu Oya. SIMULATING THE SURVEILLANCE DURATION OF INTRAVESICAL RECURRENCE AFTER RADICAL NEPHROURETERECTOMY: AN INDIVIDUALIZED RISK BASED APPROACH APPLYING THE WEIBULL MODEL. JOURNAL OF UROLOGY. 2019. 201. 4. E717-E717
ｍore...
Education (2)：
- 2016 - 2020 Keio University Graduate School of Medicine
- 2003 - 2009 Keio University School of Medicine
Professional career (1)：
Return to Previous Page
